Detalles de la búsqueda
1.
Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study.
Cancer Immunol Immunother
; 64(8): 999-1009, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-25971540
2.
Isolated limb perfusion with the tumor-targeting human monoclonal antibody-cytokine fusion protein L19-TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanoma.
J Surg Oncol
; 107(2): 173-9, 2013 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-22674435
3.
The use of polytetrafluoroethylene to facilitate the vascular access in recurrent melanoma to limbs.
Int J Surg Case Rep
; 4(1): 40-3, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23108169
4.
Limited induction of tumor cross-reactive T cells without a measurable clinical benefit in early melanoma patients vaccinated with human leukocyte antigen class I-modified peptides.
Clin Cancer Res
; 18(23): 6485-96, 2012 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23032742
5.
A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients.
Cancer Immunol Immunother
; 55(8): 958-68, 2006 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-16215718
Resultados
1 -
5
de 5
1
Próxima >
>>